STOCKHOLM, Oct. 12, 2018 /PRNewswire/ --
Oncoinvent announces that Radspherin research findings will be presented at the 32nd Annual Congress of the European Association of Nuclear Medicine (EANM) (13-17 October 2018, Düsseldorf, Germany).
The presentation is entitled:
Alpha-Emitting Radiopharmaceutical for IP Therapy of Peritoneal Metastases: In Vitro Evaluation and Therapeutic Effects in a Murine Model
Authors: T. B. Bønsdorff, E. Napoli, I. S. Jorstad, S. Westrøm, Ø. S. Bruland, R. H. Larsen
Session: EP-55 - Preclinical and translational aspects, including radiopharmacy, radiochemistry and drug development - Preclinical and translational aspects - Preclinical aspects - Animal models and in-vitro studies
Abstract No.: EP-0788
Format: Electronic poster
CONTACT:
For further information, please contact:
Jan A. Alfheim, Chief Executive Officer
Cell: +47-46-44-00-45
Email: Alfheim@oncoinvent.com
IR enquiries:
Ole Peter Nordby, Chief Financial Officer
Cell: +47-41-28-71-79
Email: nordby@oncoinvent.com
This information was brought to you by Cision http://news.cision.com
http://news.cision.com/oncoinvent-as/r/oncoinvent-to-present-and-attend-the-32nd-annual-congress-of-the-european-association-of-nuclear-med,c2643484
The following files are available for download:
http://mb.cision.com/Main/15403/2643484/925754.pdf |
